Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Viking Thera (VKTX)

Viking Thera (VKTX)
24.99 -0.67 (-2.61%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 24.95 -0.04 (-0.16%) 19:59 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
24.36
Day High
25.40
Open 25.14
Previous Close 25.66 25.66
Volume 3,960,900 3,960,900
Avg Vol 4,614,190 4,614,190
Stochastic %K 80.29% 80.29%
Weighted Alpha -68.42 -68.42
5-Day Change +1.05 (+4.39%) +1.05 (+4.39%)
52-Week Range 18.92 - 81.86 18.92 - 81.86
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,881,336
  • Shares Outstanding, K 112,289
  • Annual Sales, $ 0 K
  • Annual Income, $ -109,960 K
  • EBIT $ -151 M
  • EBITDA $ -168 M
  • 60-Month Beta 0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.26

Options Overview Details

View History
  • Implied Volatility 64.24% ( -12.13%)
  • Historical Volatility 84.33%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 134.16% on 04/08/25
  • IV Low 64.24% on 04/25/25
  • Put/Call Vol Ratio 0.26
  • Today's Volume 14,271
  • Volume Avg (30-Day) 15,813
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 190,303
  • Open Int (30-Day) 198,004

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.38
  • Number of Estimates 10
  • High Estimate -0.30
  • Low Estimate -0.46
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.92 +32.08%
on 04/09/25
Period Open: 27.98
28.19 -11.35%
on 03/26/25
-2.99 (-10.69%)
since 03/25/25
3-Month
18.92 +32.08%
on 04/09/25
Period Open: 34.50
36.39 -31.33%
on 02/21/25
-9.51 (-27.57%)
since 01/24/25
52-Week
18.92 +32.08%
on 04/09/25
Period Open: 68.86
81.86 -69.47%
on 05/07/24
-43.87 (-63.71%)
since 04/25/24

Most Recent Stories

More News
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips

Viking Therapeutics VKTX reported a first-quarter 2025 loss of 41 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents. The company had incurred a loss of 26 cents in the year-ago...

VKTX : 24.99 (-2.61%)
CTMX : 0.7100 (-7.29%)
ETNB : 6.94 (+0.58%)
ANIP : 69.82 (+0.26%)
Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic...

VKTX : 24.99 (-2.61%)
NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
GS : 544.86 (-0.09%)
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

VKTX : 24.99 (-2.61%)
NVO : 62.08 (-0.88%)
HIMS : 28.09 (-0.18%)
LLY : 884.54 (+2.89%)
PFE : 22.92 (+0.61%)
2 Stocks Down by 25% or More This Year to Buy and Hold

Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to look...

PYPL : 65.34 (+0.88%)
VKTX : 24.99 (-2.61%)
Viking Therapeutics Stock Pops But Struggles to Hold Gains

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

VKTX : 24.99 (-2.61%)
NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock is...

VKTX : 24.99 (-2.61%)
LLY : 884.54 (+2.89%)
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

VKTX : 24.99 (-2.61%)
GPCR : 23.74 (+0.38%)
PFE : 22.92 (+0.61%)
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Pfizer bows, but is not entirely out of the GLP-1 race.

VKTX : 24.99 (-2.61%)
NVO : 62.08 (-0.88%)
LLY : 884.54 (+2.89%)
GPCR : 23.74 (+0.38%)
PFE : 22.92 (+0.61%)
3 Magnificent Stocks That Could Double or More by 2030

When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant...

VKTX : 24.99 (-2.61%)
CRSP : 38.27 (-2.15%)
SMMT : 23.47 (-36.06%)
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years?

Viking Therapeutics (NASDAQ: VKTX) is a healthcare company that possesses a lot of growth potential. And last year, its shares rose by 116%, as investors were bullish on its prospects.

VKTX : 24.99 (-2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 26.51
2nd Resistance Point 25.96
1st Resistance Point 25.47
Last Price 24.99
1st Support Level 24.43
2nd Support Level 23.88
3rd Support Level 23.39

See More

52-Week High 81.86
Fibonacci 61.8% 57.82
Fibonacci 50% 50.39
Fibonacci 38.2% 42.96
Last Price 24.99
52-Week Low 18.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective